79
Views
12
CrossRef citations to date
0
Altmetric
Original Research

Targeted drugs for pulmonary arterial hypertension: a network meta-analysis of 32 randomized clinical trials

, , , , , , & show all
Pages 871-885 | Published online: 08 May 2017

Figures & data

Figure 1 Network of available drugs for PAH.

Note: The size of nodes is proportional to the number of individuals randomized to each treatment, and the thickness of lines to the number of direct comparisons in trials.
Abbreviations: ERAs, endothelin receptor antagonists; PAH, pulmonary arterial hypertension; PDE-5Is, phosphodiesterase 5 inhibitors; sGCS, soluble guanylate cyclase stimulator.
Figure 1 Network of available drugs for PAH.

Figure 2 Pooled WMD and 95% CIs determined by network meta-analysis for 6MWD of targeted drugs (A) or oral targeted drugs (B) for PAH.

Abbreviations: 6MWD, 6-minute walk distance; CI, confidence interval; ERAs, endothelin receptor antagonists; PAH, pulmonary arterial hypertension; PDE-5Is, phosphodiesterase 5 inhibitors; sGCS, soluble guanylate cyclase stimulator; WMD, weighted mean difference.
Figure 2 Pooled WMD and 95% CIs determined by network meta-analysis for 6MWD of targeted drugs (A) or oral targeted drugs (B) for PAH.

Figure 3 Pooled WMD and 95% CIs determined by network meta-analysis for mean pulmonary artery pressure of targeted drugs (A) or oral targeted drugs (B) for PAH. Pooled WMD and 95% CIs determined by network meta-analysis for pulmonary vascular resistance of targeted drugs (C) or oral targeted drugs (D) for PAH.

Abbreviations: CI, confidence interval; ERAs, endothelin receptor antagonists; mPAP, mean pulmonary artery pressure; PAH, pulmonary arterial hypertension; PDE-5Is, phosphodiesterase 5 inhibitors; PVR, pulmonary vascular resistance; sGCS, soluble guanylate cyclase stimulator; WMD, weighted mean difference.
Figure 3 Pooled WMD and 95% CIs determined by network meta-analysis for mean pulmonary artery pressure of targeted drugs (A) or oral targeted drugs (B) for PAH. Pooled WMD and 95% CIs determined by network meta-analysis for pulmonary vascular resistance of targeted drugs (C) or oral targeted drugs (D) for PAH.
Figure 3 Pooled WMD and 95% CIs determined by network meta-analysis for mean pulmonary artery pressure of targeted drugs (A) or oral targeted drugs (B) for PAH. Pooled WMD and 95% CIs determined by network meta-analysis for pulmonary vascular resistance of targeted drugs (C) or oral targeted drugs (D) for PAH.

Figure 4 Pooled OR and 95% CIs determined by network meta-analysis for all-cause mortality of targeted drugs (A) or oral targeted drugs (B) for PAH.

Abbreviations: CI, confidence interval; ERAs, endothelin receptor antagonists; OR, odds ratio; PAH, pulmonary arterial hypertension; PDE-5Is, phosphodiesterase 5 inhibitors; sGCS, soluble guanylate cyclase stimulator.
Figure 4 Pooled OR and 95% CIs determined by network meta-analysis for all-cause mortality of targeted drugs (A) or oral targeted drugs (B) for PAH.

Figure 5 Pooled OR and 95% CIs determined by network meta-analysis for clinical worsening events of targeted drugs (A) or oral targeted drugs (B) for PAH.

Abbreviations: CI, confidence interval; ERAs, endothelin receptor antagonists; OR, odds ratio; PAH, pulmonary arterial hypertension; PDE-5Is, phosphodiesterase 5 inhibitors; sGCS, soluble guanylate cyclase stimulator.
Figure 5 Pooled OR and 95% CIs determined by network meta-analysis for clinical worsening events of targeted drugs (A) or oral targeted drugs (B) for PAH.

Figure 6 Pooled OR and 95% CIs determined by network meta-analysis for SAEs of targeted drugs (A) or oral targeted drugs (B) for PAH.

Abbreviations: CI, confidence interval; ERAs, endothelin receptor antagonists; OR, odds ratio; PAH, pulmonary arterial hypertension; PDE-5Is, phosphodiesterase 5 inhibitors; SAE, serious adverse event; sGCS, soluble guanylate cyclase stimulator.
Figure 6 Pooled OR and 95% CIs determined by network meta-analysis for SAEs of targeted drugs (A) or oral targeted drugs (B) for PAH.

Figure S1 Study selection flow chart.

Abbreviation: RCT, randomized controlled trial.

Figure S1 Study selection flow chart.Abbreviation: RCT, randomized controlled trial.

Table S1 General characteristics of the included studies